361 related articles for article (PubMed ID: 37934012)
1. Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.
Wang Y; Zhou Y; Yang L; Lei L; He B; Cao J; Gao H
Adv Sci (Weinh); 2024 Jan; 11(1):e2303175. PubMed ID: 37934012
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.
Gandini S; Massi D; Mandalà M
Crit Rev Oncol Hematol; 2016 Apr; 100():88-98. PubMed ID: 26895815
[TBL] [Abstract][Full Text] [Related]
3. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.
Yin S; Chen Z; Chen D; Yan D
Theranostics; 2023; 13(5):1520-1544. PubMed ID: 37056572
[TBL] [Abstract][Full Text] [Related]
4. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
7. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
9. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Zhang J; Dang F; Ren J; Wei W
Trends Biochem Sci; 2018 Dec; 43(12):1014-1032. PubMed ID: 30287140
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Zwergel C; Fioravanti R; Mai A
Drug Discov Today; 2023 Feb; 28(2):103435. PubMed ID: 36370994
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Guo L; Wei R; Lin Y; Kwok HF
Front Immunol; 2020; 11():1508. PubMed ID: 32733486
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Liu M; Sun Q; Wei F; Ren X
Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
Córdova-Bahena L; Velasco-Velázquez MA
Rev Invest Clin; 2020 Oct; 73(1):008-016. PubMed ID: 33079077
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
15. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
16. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Xiong W; Gao Y; Wei W; Zhang J
Trends Cancer; 2021 Sep; 7(9):837-846. PubMed ID: 33903073
[TBL] [Abstract][Full Text] [Related]
17. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
18. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Udall M; Rizzo M; Kenny J; Doherty J; Dahm S; Robbins P; Faulkner E
Diagn Pathol; 2018 Feb; 13(1):12. PubMed ID: 29426340
[TBL] [Abstract][Full Text] [Related]
20. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]